Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

761.24 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 629
Open 761.24
Bid (Size) 739.75 (1)
Ask (Size) 758.00 (1)
Prev. Close 761.24
Today's Range 761.24 - 761.24
52wk Range 538.01 - 769.63
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Regeneron's Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol
 
Via Benzinga
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
 
Via Benzinga

Performance

YTD
+21.39%
+21.39%
1 Month
+0.18%
+0.18%
3 Month
+26.74%
+26.74%
6 Month
+20.70%
+20.70%
1 Year
+20.72%
+20.72%

More News

Read More
2 Market-Beating Stocks That Can Continue Rising in 2023
Via The Motley Fool
Market Currents: Why Pick Stocks?
Via Talk Markets
Stock Market Investing Action Plan: What Part Of November Don't You Understand?
Via Investor's Business Daily
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
Via Benzinga
Regeneron Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid Shortfall
Via Investor's Business Daily
Dexcom Leads 5 Stocks Near Buy Points
Via Investor's Business Daily
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
Via Benzinga
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
Via Spotlight Growth
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
Via InvestorPlace
Daily Stock Analysis: Sanofi - November 2022 Snapshot
Via Talk Markets
2 Top Biotech Stocks to Buy in November
Via The Motley Fool
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Via MarketBeat
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Via Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today
Via Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
Via InvestorPlace
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
Via Investor's Business Daily
Regeneron Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Earnings Scheduled For November 3, 2022
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Via Benzinga
Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.